Ra Capital Management, L.P. - Insider Trading & Ownership

Location
200 Berkeley Street, 18 Th Floor, Boston, MA
Summary
The estimated value of insider holdings of Ra Capital Management, L.P. is at least $1.33B dollars as of November 24, 2025. Ra Capital Management, L.P. is the Director, 10%+ Owner of Cidara Therapeutics, Inc. and owns shares of Cidara Therapeutics, Inc. (CDTX) stock worth about $167M. Ra Capital Management, L.P. is the Director of Mineralys Therapeutics, Inc. and owns shares of Mineralys Therapeutics, Inc. (MLYS) stock worth about $139M. Ra Capital Management, L.P. is the Former 10% Owner of iTeos Therapeutics, Inc. and owns shares of iTeos Therapeutics, Inc. (ITOS) stock worth about $137M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Cytek Biosciences, Inc. and owns shares of Cytek Biosciences, Inc. (CTKB) stock worth about $127M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Wave Life Sciences Ltd. and owns shares of Wave Life Sciences Ltd. (WVE) stock worth about $122M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Tyra Biosciences, Inc. and owns shares of Tyra Biosciences, Inc. (TYRA) stock worth about $117M. Ra Capital Management, L.P. is the 10%+ Owner of Fulcrum Therapeutics, Inc. and owns shares of Fulcrum Therapeutics, Inc. (FULC) stock worth about $79.4M. Ra Capital Management, L.P. is the 10%+ Owner of 4D Molecular Therapeutics, Inc. and owns shares of 4D Molecular Therapeutics, Inc. (FDMT) stock worth about $74.5M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Vor Biopharma Inc. and owns shares of Vor Biopharma Inc. (VOR) stock worth about $69.6M. Ra Capital Management, L.P. is the Director, 10%+ Owner of PepGen Inc. and owns shares of PepGen Inc. (PEPG) stock worth about $59.4M. Ra Capital Management, L.P. is the 10%+ Owner of Kala Pharmaceuticals, Inc. and owns shares of KALA BIO, Inc. (KALA) stock worth about $47.4M. Ra Capital Management, L.P. is the Director, 10%+ Owner of 89bio, Inc. and owns shares of 89bio, Inc. (ETNB) stock worth about $36.8M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Bicara Therapeutics Inc. and owns shares of Bicara Therapeutics Inc. (BCAX) stock worth about $35.1M. Ra Capital Management, L.P. is the Former 10% owner of Enliven Therapeutics, Inc. and owns shares of Enliven Therapeutics, Inc. (ELVN) stock worth about $32.1M. Ra Capital Management, L.P. is the 10%+ Owner of Solid Biosciences Inc. and owns shares of Solid Biosciences Inc. (SLDB) stock worth about $15M. Ra Capital Management, L.P. is the Director of Therapeutics Acquisition Corp. and owns shares of POINT Biopharma Global Inc. stock worth about $13.7M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Climb Bio, Inc. and owns shares of Climb Bio, Inc. (CLYM) stock worth about $11M. Ra Capital Management, L.P. is the 10%+ Owner of RxSight, Inc. and owns shares of RxSight, Inc. (RXST) stock worth about $10.3M. Ra Capital Management, L.P. is the Director of Black Diamond Therapeutics, Inc. and owns shares of Black Diamond Therapeutics, Inc. (BDTX) stock worth about $8.77M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Septerna, Inc. and owns shares of Septerna, Inc. (SEPN) stock worth about $8.61M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Sionna Therapeutics, Inc. and owns shares of Sionna Therapeutics, Inc. (SION) stock worth about $6.28M. Ra Capital Management, L.P. is the Director, 10%+ Owner of Werewolf Therapeutics, Inc. and owns shares of Werewolf Therapeutics, Inc. (HOWL) stock worth about $6.11M. Ra Capital Management, L.P. is the 10%+ Owner of Aerovate Therapeutics, Inc. and owns shares of Jade Biosciences, Inc. (JBIO) stock worth about $3.44M. Ra Capital Management, L.P. is the 10%+ Owner of AN2 Therapeutics, Inc. and owns shares of AN2 Therapeutics, Inc. (ANTX) stock worth about $325K. Ra Capital Management, L.P. is the Director, 10%+ Owner of Janux Therapeutics, Inc. and owns shares of Janux Therapeutics, Inc. (JANX) stock worth about $160K. Ra Capital Management, L.P. is the Director, 10%+ Owner of Acumen Pharmaceuticals, Inc. and owns shares of Acumen Pharmaceuticals, Inc. (ABOS) stock worth about $14.1K.
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
All Insider Reports
All Insider Reports

Ownership of Ra Capital Management, L.P.

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CDTX Cidara Therapeutics, Inc. Director, 10%+ Owner $167M +$100M +149% Jun 26, 2025
MLYS Mineralys Therapeutics, Inc. Director $139M +$47.5M +51.8% Sep 4, 2025
ITOS iTeos Therapeutics, Inc. Former 10% Owner $137M May 10, 2024
CTKB Cytek Biosciences, Inc. Director, 10%+ Owner $127M Mar 14, 2022
WVE Wave Life Sciences Ltd. Director, 10%+ Owner $122M +$6.69K +0.01% Nov 13, 2025
TYRA Tyra Biosciences, Inc. Director, 10%+ Owner $117M +$15.3M +15.1% Jun 12, 2025
FULC Fulcrum Therapeutics, Inc. 10%+ Owner $79.4M Sep 12, 2024
FDMT 4D Molecular Therapeutics, Inc. 10%+ Owner $74.5M Dec 9, 2024
VOR Vor Biopharma Inc. Director, 10%+ Owner $69.6M -$33.7M -32.6% Oct 28, 2025
PEPG PepGen Inc. Director, 10%+ Owner $59.4M +$30M +102% Sep 26, 2025
KALA KALA BIO, Inc. 10%+ Owner $47.4M May 26, 2022
ETNB 89bio, Inc. Director, 10%+ Owner $36.8M +$50M Oct 30, 2025
BCAX Bicara Therapeutics Inc. Director, 10%+ Owner $35.1M Jun 9, 2025
ELVN, IMRA Enliven Therapeutics, Inc. Former 10% owner $32.1M Feb 23, 2023
SLDB Solid Biosciences Inc. 10%+ Owner $15M +$15M Feb 19, 2025
PNT POINT Biopharma Global Inc. Director $13.7M Jun 29, 2021
CLYM Climb Bio, Inc. Director, 10%+ Owner $11M Jun 4, 2025
RXST RxSight, Inc. 10%+ Owner $10.3M Aug 3, 2021
BDTX Black Diamond Therapeutics, Inc. Director $8.77M Jul 5, 2023
SEPN Septerna, Inc. Director, 10%+ Owner $8.61M Jun 17, 2025
SION Sionna Therapeutics, Inc. Director, 10%+ Owner $6.28M -$21.5M -77.4% Nov 20, 2025
HOWL Werewolf Therapeutics, Inc. Director, 10%+ Owner $6.11M +$487K +8.66% May 12, 2025
JBIO Jade Biosciences, Inc. 10%+ Owner $3.44M Apr 28, 2025
ANTX AN2 Therapeutics, Inc. 10%+ Owner $325K Aug 9, 2024
JANX Janux Therapeutics, Inc. Director, 10%+ Owner $160K +$25.3M Jun 11, 2025
ABOS Acumen Pharmaceuticals, Inc. Director, 10%+ Owner $14.1K Jun 4, 2025
ICVX Icosavax, Inc. Director, 10%+ Owner $0 Feb 19, 2024
ACRV Acrivon Therapeutics, Inc. Director, 10%+ Owner Jun 13, 2025
SPRY ARS Pharmaceuticals, Inc. Director, 10%+ Owner Jun 25, 2025
ARTV Artiva Biotherapeutics, Inc. Director, 10%+ Owner Jun 24, 2025
BOLD Boundless Bio, Inc. 10%+ Owner Apr 2, 2024
DICE DICE Therapeutics, Inc. Former 10% owners and Director Aug 9, 2023
EVMN Evommune, Inc. Director, 10%+ Owner Nov 7, 2025
FMTX Forma Therapeutics Holdings, Inc. Director, 10%+ Owner Oct 14, 2022
LENZ LENZ Therapeutics, Inc. Director, 10%+ Owner Jun 11, 2025
NKTX Nkarta, Inc. Director, 10%+ Owner Jun 5, 2025
STSA Satsuma Pharmaceuticals, Inc. Former 10% Owner Jun 8, 2023

Insider Transactions Reported by Ra Capital Management, L.P.:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.